Comparative Pharmacology
Head-to-head clinical analysis: AKRINOL versus TAZORAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKRINOL versus TAZORAC.
AKRINOL vs TAZORAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
Adults: 100 mg orally twice daily.
Apply a pea-sized amount to affected areas once daily in the evening. Tazorac is available as a 0.05% or 0.1% gel or cream. For plaque psoriasis, the 0.1% gel is typically used. For acne, the 0.1% cream or gel is started, then decreased to 0.05% if irritation occurs.
None Documented
None Documented
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless CrCl <30 mL/min).
Terminal elimination half-life of tazarotenic acid is approximately 18 hours (range 7-30 hours) after topical application, allowing once-daily dosing; systemic exposure is low due to extensive protein binding and slow clearance.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Primarily fecal: approximately 60-70% eliminated in feces (as metabolites), renal excretion accounts for <10% as unchanged drug and metabolites, with <1% as unchanged tazarotenic acid.
Category C
Category C
Topical Retinoid
Topical Retinoid